Nasdaq and S&P 500 see the biggest single-day gain in two weeks
Choice is between democratic openness and parasitical elites having their way
Ramaphosa gave the Special Investigating Unit the green light to investigate allegations against the two boards earlier in August
The party has decided there should not be a cooling-off period as provided for in the Electoral Amendment Bill
Evraz is under sanctions by the UK and EU after Russia’s invasion of Ukraine
The improved sentiment is a result of increased merchandise export and import volumes and more new vehicles sold, Sacci report says
Emergence from EU’s enhanced surveillance framework will allow the country greater freedom in making economic policy
Fiery hooker comes in as coach Jacques Nienaber reshuffles front row for All Blacks showdown
Now more than ever, there are tangible reasons to believe that Africa’s time is now as major firms invest in African brands, from music and art to fashion
When I wrote about consumer health and care group Ascendis several months ago, there was a little bit of drama surrounding the article.
First, CEO Karsten Wellner called me up to challenge my comments. I had noted that the return on equity was low for a supposedly fast-growing company. I also believed that acquisitions were overpriced, and he assured me that Ascendis was not in fact paying too much for its foreign targets.
And second, I berated the Business Day subeditors for a headline about the group "bleeding", when indeed the results were then looking okay.
Fast forward to the next reporting period, and with the publication of Ascendis Health interim results to December 2017, the drama continues.
First, Wellner is no longer the CEO, vacating this position almost instantly, being replaced by London-based Thomas Thomsen, who previously ran the European businesses of Ascendis. And second, huge apologies to the subs. They seemed to know what was ahead as Ascendis is now indeed a bit...
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email firstname.lastname@example.org or call 0860 52 52 00. Got a subscription voucher? Redeem it now
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.